Dec 10, 2019 - increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Dec 10, 2019 - Sanofi, with sales falling in its older businesses, boosts its higher-growth immuno-oncology business with the $2.5 billion purchase of Synthorx.
Dec 10, 2019 - Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Dec 10, 2019 - Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.
Dec 10, 2019 - Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.
Dec 10, 2019 - Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.
Dec 09, 2019 - Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.
Dec 06, 2019 - Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.
Nov 29, 2019 - Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
Nov 25, 2019 - Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.